| Business Summary | | Maxxon,
Inc.
owns
the
exclusive
license
to
develop,
manufacture
and
market
a
patented
disposable
safety
syringe,
called
the
Maxxon
Safety
Syringe,
which
retracts
the
needle
into
the
barrel
of
the
syringe
after
an
injection
has
been
given.
The
Company
seeks
to
develop
and
market
a
commercially
viable
hypodermic
syringe
that
reduces
the
risk
of
accidental
needlestick
injuries.
These
injuries
pose
a
serious
risk
of
transmitting
fatal
or
chronic
diseases
to
healthcare
workers.
The
Company
has
not
yet
begun
the
Food
and
Drug
Administration
approval
process.
The
Maxxon
Safety
Syringe
accomplishes
the
needle
retraction
with
a
vacuum.
As
the
syringe
is
being
used,
a
vacuum
is
created,
and
when
the
plunger
is
released,
the
needle
is
forced
into
the
interior
of
the
barrel
by
the
pressure
differential.
Once
inside,
the
needle
will
remain
indefinitely,
substantially
reducing
the
risk
of
accidental
needlestick
injuries. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Maxxon,
Inc.
is
a
developer
and
marketer
of
selected
healthcare
products.
The
Company
has
acquired
an
exclusive
license
to
develop
and
market
a
patented
disposable
syringe
that
automatically
retracts
the
needle
into
the
plunger
after
use.
For
the
six
months
ended
6/30/01,
revenues
totaled
$177
thousand
vs.
none.
Net
loss
totalled
$874
thousand,
up
from
$360
thousand.
Results
reflect
increased
investment
income,
offset
by
higher
R&D
and
SG&A
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Gifford Mabie, 60 | Chairman
and CEO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|